Connect with us
Abivax shares surged nearly 36% after positive updated trial results for its ulcerative colitis drug obefazimod reassured investors following earlier safety concerns. New data showed strong...
The inflammatory bowel disease market is rapidly growing, driven by unmet patient needs despite existing therapies. Major pharma acquisitions highlight strong demand for innovative treatments. Abivax’s...
The publication of the results of the phase IIa clinical trial, evaluating ABX464 in hemorrhagic recto colitis, has been driving the stock market price of Montpellier...